LIGHTPATH TECHNOLOGIES INC
For the period ended Sep 30, 2024. Filed Nov 7, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2024 · Filed Nov 7, 2024
LPTH$7.99-0.2%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Unaudited Condensed Consolidated Statement of Changes in Stockholders’ Equity
| LIGHTPATH TECHNOLOGIES, INC. | ||||||
|---|---|---|---|---|---|---|
| Condensed Consolidated Statements of Changes in Stockholders' Equity | ||||||
| (unaudited) | ||||||
| Accumulated | ||||||
| Class A · Additional · Other · Total | ||||||
| Common Stock · Paid-in · Comprehensive · Accumulated · Stockholders’ | ||||||
| Shares | Amount | Capital | Income | Deficit | Equity | |
| Balances at June 30, 2024 | 39,254,643 | $392,546 | $245,140,758 | $509,936 | $(215,843,575) | $30,199,665 |
| Issuance of common stock for: | ||||||
| Employee Stock Purchase Plan | 8,232 | 82 | 10,290 | — | — | 10,372 |
| Exercise of Stock Options, RSUs & RSAs, net | 70,309 | 703 | (703) | — | — | — |
| Issuance of common stock for acquisition of Visimid | 279,553 | 2,796 | 318,562 | — | — | 321,358 |
| Stock-based compensation on stock options, RSUs & RSAs | — | — | 264,475 | — | — | 264,475 |
| Foreign currency translation adjustment | — | — | — | 271,594 | — | 271,594 |
| Net loss | — | — | — | — | (1,622,745) | (1,622,745) |
| Balances at September 30, 2024 | 39,612,737 | $396,127 | $245,733,382 | $781,530 | $(217,466,320) | $29,444,719 |
| Balances at June 30, 2023 | 37,344,739 | $373,447 | $242,808,771 | $606,536 | $(207,836,229) | $35,952,525 |
| Issuance of common stock for: | ||||||
| Employee Stock Purchase Plan | 14,607 | 146 | 19,573 | — | — | 19,719 |
| Exercise of Stock Options, RSUs & RSAs, net | 14,482 | 145 | (145) | — | — | — |
| Issuance of common stock for acquisition of Visimid | 81,610 | 816 | 149,184 | — | — | 150,000 |
| Stock-based compensation on stock options, RSUs & RSAs | — | — | 240,075 | — | — | 240,075 |
| Foreign currency translation adjustment | — | — | — | (125,208) | — | (125,208) |
| Net loss | — | — | — | — | (1,342,376) | (1,342,376) |
| Balances at September 30, 2023 | 37,455,438 | $374,554 | $243,217,458 | $481,328 | $(209,178,605) | $34,894,735 |
The accompanying notes are an integral part of these condensed consolidated financial statements.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.